Related Experiment Video
Updated: Jun 5, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
Leukotriene inflammatory mediators meet their match
1Department of Physiology, Queen's University, Kingston, ON K7L 3N6, Canada. funkc@queensu.ca
Abstract:
Leukotrienes are arachidonic acid-derived lipid mediators of inflammation. The initial catalytic step in the formation of leukotrienes is catalyzed by 5-lipoxygenase (5-LOX) in conjunction with its activating partner protein FLAP. The long-awaited crystal structure of 5-LOX--reported in a recent issue of Science--should lead to novel, purpose-designed inhibitors for the treatment of asthma and for probing leukotriene involvement in cardiovascular disease and cancer.
Related Concept Videos
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma I: Introduction
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Acute Inflammation I: Inflammatory Response
Acute Inflammation II: Cellular Phase

